Medical Conference Calendar 2026
Key venues for Phase 2/3 trial readouts, late-breaking data, and FDA decisions · 49 conferences in 2026
Key presentations tracked as they happen
Curated selection of key Phase 2/3 readouts and late-breaking abstracts from major pharma (not a complete list). Currently tracking 7 presentations across 5 conferences so far.
August 2026
European cardiovascular data. Often presents pivotal cardiovascular outcomes trials.
September 2026
European respiratory. IPF, asthma, COPD, lung cancer readouts.
European dermatology. 5,300+ abstracts in 2025. Atopic dermatitis, psoriasis, HS late-breaking trials. Tralokinumab, icotrokinra, rocatinlimab, izokibep data typically presented here.
European diabetes and metabolic disease data. Often first presentation of EU trial data.
World's largest lung cancer conference. NSCLC, SCLC, mesothelioma. EGFR, ALK, MET, KRAS, IO combinations. AstraZeneca, Roche, Merck, BMS, Pfizer, Novartis present landmark data here.
Multiple sclerosis focused. Key venue for new MS DMT data.
October 2026
Europe's largest applied neuroscience and psychiatry meeting. Depression, schizophrenia, bipolar, anxiety, ADHD. J&J, Pfizer, AstraZeneca, Lundbeck CNS pipelines.
Largest US ophthalmology conference (~20,000 attendees). Wet AMD, diabetic retinopathy, geographic atrophy, gene therapy. Roche (faricimab/Vabysmo), Regeneron (Eylea HD), Novartis.
Pulmonology and critical care — asthma, COPD, PAH, IPF, sleep medicine. Sotatercept (Merck) PAH data, dupilumab long-term, GLP-1 and OSA. Complements ATS with fall conference.
CKD, dialysis, transplant, IgA nephropathy. Key for new SGLT2 and finerenone data.
Premier European oncology meeting. Often European data complements ASCO US data.
Interventional cardiology — structural heart, ACS, coronary intervention. Anticoagulant and antiplatelet drug trials alongside devices. Roche, BMS, AstraZeneca, Bayer.
November 2026
Premier obesity clinical science conference. GLP-1 revolution: semaglutide, tirzepatide secondary analyses, real-world data, new obesity drugs. Novo Nordisk, Eli Lilly, AstraZeneca, Pfizer, Roche obesity programs.
Key for checkpoint inhibitors, CAR-T, cancer vaccines, and immuno-oncology combinations.
Stroke, heart failure, hypertension, atrial fibrillation readouts.
RA, PsA, SLE, ankylosing spondylitis, IBD. Key for JAK inhibitors, IL-17/23 data.
NASH/MASH, HCC, hepatitis B/C, liver transplant. Key for FXR agonists, resmetirom, thyroid hormone analogs.
Neuro-oncology — glioblastoma, brain metastases, CNS lymphoma. CAR-T in GBM, checkpoint inhibitors in CNS tumors. Roche, Merck, BMS, AstraZeneca, emerging CAR-T programs.
The primary conference for Alzheimer's clinical trial readouts. Distinct from AD/PD (which is broader). Biogen/Eisai (lecanemab), Eli Lilly (donanemab), Roche (gantenerumab), Merck, Novo Nordisk CNS programs present here.
December 2026
Key venue for leukemia, lymphoma, myeloma, and blood disorder data.
Key Presentations
Curated selection of 7 notable readouts (not comprehensive)
Earlier in 2026
2025 Conference Archive
41 conferences — dates, locations, and presentations
Matching trial readouts to conferences
When a Phase 2 or Phase 3 trial's Primary Completion Date falls in the months before a major conference in the same disease area, that conference is the most likely venue for the readout.
| Disease area | Primary readout venue | Abstract window |
|---|---|---|
| Solid tumors | ASCO (Jun), ESMO (Sep) | Jan–Feb for ASCO; Apr–May for ESMO |
| Hematology | ASH (Dec), ASCO (Jun) | Jun for ASH; Jan–Feb for ASCO |
| Cardiovascular | ACC (Mar), AHA (Nov), ESC (Aug) | Oct for ACC; Apr for ESC |
13 more disease areas
Unlock with Pro · $99/mo →